Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.9652W HIGH $18.89
Volume
75.19 K
Value Traded
60.93 M
Short % Float
9.3%
Days to Cover
2.6
-0.38%Week
-3.54%1 Month
+19.85%3 Month
+168.14%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.66 B
EPS (TTM)
-1.00
P/E Ratio
-
Ent. Value
1.44 B
Total Shares
104.79 M
Float Shares
73.01 M
Insiders
32.64%
Institutions
59.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PSNL Catalyst Timeline
Dated clinical, regulatory and corporate events for Personalis, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Personalis, Inc.
7Total events
0Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
▲Reimbursement / PricingPost-Market
Medicare coverage secured for NeXT Personal for neoadjuvant breast cancer monitoring
neoadjuvant therapy monitoring in Stage II-III TNBC or HER2+ breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How PSNL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Personalis, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PSNL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pembrolizumab | high-risk stage II-III dMMR/MSI-H colorectal cancer | 2026-04-21 | 100% sensitivity for disease at baseline; 100% of 'super molecular responders' achieved pCR; 100% of 'poor molecular responders' did not achieve pCR; 100% negative predictive value (NPV) post-surgery; 100% specificity for disease relapse; 39% of all positive MRD detections occurred in the ultrasensitive range below 100 PPM; 14.6% below 10 PPM; >99.9% specificity for resistance mutations; 38% of MRD-positive patients had resistance mutations; 100% progression-free at three years for patients with durable molecular complete responseRead More | Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tachibana AaronOfficer (CFO AND COO) | Sell | -2,931 195,902 held | $16.22 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PSNL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.8 % (166.7 %) | 53.60 M | 4.00 M | 33.33% ( 1.00 M) |
Ownership Trends
PSNL Short Interest
Shares sold short, counted twice a month.
9.3%
Short % of Float
of tradable shares sold short
6.8M
Shares Sold Short
-19.4% vs prior count
2.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PSNL ranks across every disease it competes in
Competitive Position is a premium feature
See how PSNL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPSNL News
-PSNL
Oct 21, 2026Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Personalis, Inc. announced that its NeXT Personal ultrasensitive ctDNA test will be featured at ESMO 2026. The presentations include data from the C-POST Phase 3 study and the B-STRONGER-1 study, which evaluates the test's effectiveness in early-stage triple-negative breast cancer. The findings aim to enhance monitoring of treatment responses.
Read more →-PSNL
Oct 20, 2026Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
Personalis, Inc. launched the Real-Time Variant Tracker for its NeXT Personal MRD test. This new feature identifies clinically relevant resistance mutations and targetable variants as cancer evolves. The tracker aims to enhance patient management by monitoring changes in cancer biology over time. It becomes commercially available on October 20, 2026.
Read more →-PSNL
Aug 4, 2026Personalis Reports Second Quarter Results and Recent Highlights
Personalis, Inc. reported its second quarter results for 2026, showcasing significant achievements, including the receipt of Medicare coverage for its NeXT Personal immunotherapy monitoring service. This coverage is aimed at patients with late-stage solid tumors, reflecting the company's commitment to enhancing precision oncology. The report highlights operational successes that may position Personalis for future growth.
Read more →-PSNL
Jul 20, 2026▼ -13.3%on this news
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Tempus AI, Inc. has announced its acquisition of Personalis, Inc. to enhance its precision oncology platform. This strategic move aims to improve capabilities in minimal residual disease (MRD), allowing for better patient support throughout diagnosis, treatment selection, and monitoring. The integration is expected to significantly advance Tempus' AI-driven healthcare solutions.
Read more →-PSNL
Jul 14, 2026Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
Personalis, Inc. has achieved UKCA marking for its NeXT Personal Dx test, allowing clinical use in Great Britain. This milestone enhances the company's ability to support biopharma clients and enables earlier detection of cancer recurrence. The NeXT Personal Dx test is designed for ultrasensitive MRD detection, improving patient outcomes and streamlining drug development.
Read more →-PSNL
Jun 9, 2026Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis has announced the launch of CE-IVD marked specimen collection kits aimed at supporting global biopharma initiatives. These kits are designed to enhance the efficiency of specimen collection while ensuring compliance with European regulations. The move is expected to bolster Personalis's position in the biopharma market.
Read more →-PSNL
Jun 2, 2026Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis presented findings on early colorectal cancer recurrence detection and the performance of ultrasensitive minimal residual disease (MRD) detection across various tumor types at ASCO 2026. The details of the findings were not disclosed in the article.
Read more →-PSNL
May 26, 2026▲ +5.5%on this news· ran to +35% by day 3
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Personalis will showcase the capabilities of its NeXT Personal® ultra-sensitive ctDNA data at the ASCO 2026 Annual Meeting. The presentation will include insights from the TRACERx Consortium, highlighting the advancements in cancer detection and monitoring. This event aims to emphasize the importance of ctDNA in personalized medicine.
Read more →-PSNL
May 20, 2026▲ +12.9%on this news· ran to +27% by day 3shared move
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis has successfully secured a fourth Medicare coverage decision for its NeXT Personal® test, which now includes coverage for pre-surgical treatment monitoring in breast cancer patients. This expansion is expected to enhance patient care by providing more comprehensive monitoring options. The decision reflects growing recognition of the test's value in personalized cancer treatment.
Read more →-PSNL
May 14, 2026▲ +5%on this news
Personalis to Participate in Upcoming Investor Events
Personalis is set to participate in upcoming investor events, showcasing its commitment to engaging with stakeholders. The events aim to provide insights into the company's progress and future plans. Further details about the events and their significance were not disclosed in the article.
Read more →-PSNL
May 13, 2026▲ +5.8%on this newsshared move
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis has secured Medicare coverage for its NeXT Personal® test, which is designed for immunotherapy monitoring in patients with late-stage solid tumors. This development is expected to improve access to personalized cancer treatment options. The coverage represents a significant advancement in the integration of genomic testing into clinical practice.
Read more →-PSNL
May 7, 2026Personalis Reports First Quarter Results and Recent Highlights
Personalis has reported its first quarter results, but the article provides minimal details on financial performance or significant highlights. The content is primarily focused on privacy aspects, leaving out critical business insights. Stakeholders may find the lack of concrete information concerning.
Read more →-PSNL
Apr 23, 2026▼ -6.5%on this news
Personalis to Announce First Quarter 2026 Financial Results
Personalis, Inc. will announce its first quarter 2026 financial results on May 7, 2026. The company will host a conference call and webcast at 2:00 p.m. PT to discuss these results and recent highlights. Interested parties can access the call via phone or through the company's website.
Read more →-PSNL
Apr 21, 2026Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
Personalis, Inc. presented promising clinical data at the AACR Annual Meeting, showcasing the effectiveness of their NeXT Personal ultrasensitive ctDNA assay in monitoring treatment responses and tracking therapy resistance. Key findings included high sensitivity in detecting disease and the introduction of a new feature for real-time tracking of mutations. These advancements could significantly enhance cancer management strategies.
Read more →-PSNL
Apr 13, 2026Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis and its collaborators are set to present new data on ultrasensitive ctDNA and advancements in therapy resistance tracking at the AACR 2026 conference. This presentation aims to showcase the latest developments in cancer diagnostics and treatment monitoring. Further details on the findings and implications will be revealed during the event.
Read more →-PSNL
Feb 27, 2026Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis, Inc. reported significant growth in 2025, highlighted by a 400% increase in clinical volume and new Medicare coverage for breast and lung cancer. The company anticipates a robust financial outlook for 2026, projecting a five-fold increase in clinical revenue. CEO Chris Hall emphasized the importance of their 'Win-in-MRD' strategy and a strong cash position to support expansion efforts.
Read more →-PSNL
Feb 18, 2026▲ +5%on this news
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
Personalis, Inc. will participate in the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, in Boston. The company's management team will present its advancements in genomics for precision oncology. Personalis aims to enhance cancer management through personalized testing and advanced insights into tumor profiling.
Read more →-PSNL
Feb 2, 2026Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Personalis, Inc. has published a study demonstrating the effectiveness of its NeXT Personal test in monitoring immunotherapy responses in advanced cancer patients. The study, conducted by UC San Diego researchers, highlights the assay's ultrasensitive detection of circulating tumor DNA (ctDNA), which can lead to earlier clinical interventions. This research builds on previous findings and emphasizes the need for improved monitoring tools in cancer treatment.
Read more →-PSNL
Jan 29, 2026Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. The event will take place at the Cliff Lodge in Snowbird, Utah. The company focuses on advanced genomics for precision oncology, providing personalized testing and insights for cancer management.
Read more →-PSNL
Jan 8, 2026▼ -10.4%on this news
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis, Inc. reported preliminary financial results for Q4 and full year 2025, noting a substantial increase in clinical test volumes and a strong cash position. The company's revenue for Q4 is projected between $17 and $18 million, contributing to a total expected annual revenue of $69 to $70 million. Notably, Personalis secured Medicare coverage for breast cancer surveillance, a key milestone that enhances its market position. However, revenue for 2025 is anticipated to fall short of 2024 figures, presenting concerns about future growth.
Read more →About Personalis, Inc.
Headquarters6600 DUMBARTON CIRCLE, FREMONT, CA, 94555
BIOPHARMAWATCH ELITE PLUS
Trade the next PSNL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime